98%
921
2 minutes
20
Demographic data for patients with Hypermobile Ehlers-Danlos Syndrome (hEDS) has not been well established. hEDS patients often present with a constellation of symptoms; it is important to update clinical criteria for diagnosis and provide a framework for common co-morbidities. The primary objective of this study was to identify the prevalence of co-morbidities in hEDS patients to allow clinicians to better identify patients and their most common symptoms. The goal is to use this information to augment diagnostic and clinical demographic data to more accurately represent hEDS patients. This retrospective chart review utilized patient intake forms from 154 patients diagnosed with Hypermobile Ehlers-Danlos Syndrome in a clinic. Patient intake forms included responses to questions about the presence of various current and previous conditions. Our study revealed numerous co-morbidities with increased prevalence that differed from the current diagnostic criteria including Postural Orthostatic Tachycardia Syndrome, Mast Cell Activation Syndrome, anxiety, depression, Temporomandibular Joint Syndrome, headaches, and Gastroesophageal Reflux Disease. These findings will help inform clinicians of prevalent co-morbidities among hEDS patients and encourage further evaluation for screening and diagnosis. Hypermobile Ehlers-Danlos Syndrome patients presented with a wide range of co-morbidities not listed on current clinical criteria. Future studies are warranted across diverse and larger patient populations and beyond self-reported data.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/PHM.0000000000002766 | DOI Listing |
Rev Med Interne
August 2025
AP-HP, Centre de référence des syndromes d'Ehlers-Danlos non vasculaires, CHU Raymond-Poincaré, Garches, France.
Ehlers-Danlos syndromes (EDS) are a heterogeneous group of rare and inherited connective tissue disorders characterized by the following clinical triad: joint hypermobility, skin hyperelasticity and tissue fragility. Thirteen subtypes of EDS were described in 2017 by an international consortium: there are 12 subtypes with an identified genetic etiology, and the most frequent hypermobile EDS of which the molecular basis remains unknown. EDS are complex and multisystemic pathologies, with a wide clinical and genetical heterogeneity.
View Article and Find Full Text PDFGenes (Basel)
July 2025
Department of Medical Genetics, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain.
Diagnosing hypermobility disorders and Ehlers-Danlos syndrome (EDS) in children is challenging due to overlapping features with generalized joint hypermobility (GJH) and the lack of biomarkers. : This study aims to describe the clinical and genetic features of pediatric EDS patients and identify key comorbidities and correlations. : This is a single-center observational study of patients under 18 diagnosed with suspicion of EDS (2018-2024) at a tertiary pediatric hospital.
View Article and Find Full Text PDFJ Clin Med
August 2025
Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC 29407, USA.
Hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSDs) are prevalent, complex conditions marked by chronic pain, joint instability, and multisystem involvement. Despite affecting an estimated 1 in 500 individuals, these conditions remain poorly understood and inconsistently diagnosed. This study aimed to define their clinical burden through a large-scale, international survey.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of General Internal Medicine, Mayo Clinic, Jacksonville, FL, United States.
Background: In 2017 a revised clinical criterion for the diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) was proposed in order to better distinguish hEDS from other joint hypermobility disorders which are termed hypermobility spectrum disorders (HSD). The goal of this study was to determine whether patients with localized HSD (L-HSD) or historical HSD (H-HSD) differed in 100 symptoms/comorbidities from controls and/or patients diagnosed with hEDS or HSD.
Methods: In this study, we examined 100 self-reported symptoms/comorbidities from 2,695 patients diagnosed with hEDS, HSD, L-HSD/H-HSD, or controls.
Am J Med Open
December 2025
Medical Genetics, Pediatrics, Atrius Health, Boston, Mass.
Background: Hypermobile Ehlers-Danlos syndrome (hEDS) affects multiple systems, but comprehensive evaluations of a larger sample of hEDS patients are lacking. The objective of this study was to describe cerebrovascular, autonomic, and neuropathic features of hEDS.
Methods: This retrospective case-control study was conducted at Brigham and Women's Faulkner Hospital between 2016-2023.